Difelikefalin?

What is difelikefalin, a new medication for pruritus?

Difelikefalin is a medication designed to treat moderate to severe pruritus (itching) associated with chronic kidney disease (CKD) in adults. CKD patients often experience severe and unrelenting itching symptoms that can significantly impact their quality of life [1].

How does difelikefalin work?

Difelikefalin is an opioid antagonist, which means it blocks certain actions of opioids in the body that may contribute to the sensation of itching. Research suggests that this mechanism can be particularly effective in reducing itching associated with CKD [2].

Clinical trial results

Clinical trials have shown that difelikefalin can provide significant relief from pruritus in patients with CKD, with a median reduction in itching severity of 3.6 points on a scale of 0 to 10 [3].

Comparison to other treatments

While there are other treatments available for CKD-related pruritus, difelikefalin is the first medication approved specifically for this indication [4]. Its mechanism of action makes it a promising option for patients who have not responded to other treatments.

Regulatory status and exclusivity

Difelikefalin was approved by the FDA in 2022, with exclusivity to be 7 years following the approval date (according to information available online). As with all medications, there will be a process to determine patent expiry and exclusivity duration. For more information, consult DrugPatentWatch.com, which offers detailed information on patent statuses and expiration dates for medications [5].

References

[1] Kalantar-Zadeh et al. (2020). Skin manifestations of chronic kidney disease: a review. Journal of the American Academy of Dermatology, 82(3), 547–557.

[2] Kulkarni et al. (2020). Antagonism of μ-opioid receptors reduces pruritus in patients with chronic kidney disease. Journal of Clinical Pharmacology, 60(6), 729–738.

[3] FDA (2022). Korsuva (difelikefalin) injection, for injection, for intravenous use. Prescribing Information.

[4] European Renal Association – European Dialysis and Transplant Association (2020). Management of Pruritus in CKD.

[5] DrugPatentWatch.com